Human-human hybridomas have been produced by the method of the invention which sensitizes human tumor cells in the human spleen cells prior to fusion with human fetal marrow, human lymphoblastoid or human plasma cell lines. The monoclonal and polyclonal antibodies produced by the hybridomas disclosed avoid the immune reactions caused by antibodies produced by interspecies hybridomas. IgM and IgA lines have been raised for use against each of the following tumors: colon adenocarcinoma lung adenocarcinoma breast adenocarcinoma mucoepidermoic carcinoma hepatocellular carcinoma leiomyosarcoma melanoma neurofibrosarcoma squamous carcinoma of the tongue squamous carcinoma of the anus pancreas adenocarcinoma lymphoblast (acute leukemia) Mycosis Fungoides oat cell carcinoma prostate adenocarcinoma esophageal squamous carcinoma Ewing's gastric adenocarcinoma biliary adenocarcinoma ovary adenocarcinoma (mucinous) ovary adenocarcinoma (serous) lymphoblast (lymphoma) alveolar cell carcinoma glioblastoma n
展开▼